Evaluation of the VIDAS Cytomegalovirus (CMV)‐IGRA for Assessing CMV‐Specific T‐Cell Responses in Immunocompetent and Immunosuppressed Individuals

Documenti analoghi

• Cytomegalovirus IL‐10 in Plasma as a Marker of Active Infection in Allogeneic Hematopoietic Transplant Recipients: An Exploratory Study
  di: Ángela Sánchez‐Simarro, et al.
  Pubblicazione: (2026)
• Letermovir use may impact on the Cytomegalovirus DNA fragmentation profile in plasma from allogeneic hematopoietic stem cell transplant recipients
  di: Estela Giménez, et al.
  Pubblicazione: (2024)
• Dynamics of SARS‐CoV‐2 Spike Receptor‐Binding Domain‐Targeted Specific Peripheral Memory B Cells in Patients With End‐Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID‐19 Vaccination
  di: Ángela Sánchez‐Simarro, et al.
  Pubblicazione: (2025)
• Neutralizing Antibody and T‐Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1‐Adapted mRNA COVID‐19 Vaccine in Immunosuppressed and Healthy Individuals
  di: Ángela Sánchez‐Simarro, et al.
  Pubblicazione: (2025)
• Cytomegalovirus UL21‐5 mRNAemia as a Marker of Active Virus Replication in Allogeneic Hematopoietic Transplant Recipients
  di: Carlos Solano de la Asunción, et al.
  Pubblicazione: (2025)